RxDoctor Payments Data

Eboni Farmer

Family · Greensboro, NCNPI 1891447314

Payments from drug & device makers

$9,652in general payments, 2019–2025

Across 524 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$950
  • Novo Nordisk$864
  • AstraZeneca$853
  • GSK$673
  • Bayer$631
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$9,40297%
  • Education$2503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,652 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$84,830
MounjaroTirzepatide54$74,787
JardianceEmpagliflozin67$62,050
FarxigaDapagliflozin Propanediol65$54,464
GemtesaVibegron65$45,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$39,371
EliquisApixaban43$33,722
RybelsusSemaglutide18$31,112
TrulicityDulaglutide23$23,676
VraylarCariprazine Hcl13$21,540
LinzessLinaclotide28$20,810
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$18,369
Repatha SureclickEvolocumab28$16,758
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$16,497
TrintellixVortioxetine Hydrobromide27$14,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$864$115,94294 claims
Lilly USA, LLCMounjaro, Trulicity$1,017$98,46377 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$853$75,593107 claims
Boehringer IngelheimJardiance$330$62,05067 claims
Sumitomo Pharma America, Inc.Gemtesa$150$45,67065 claims
AbbVieVraylar, Linzess, Synthroid$950$43,85457 claims
GSKTrelegy Ellipta$673$39,37147 claims
PfizerEliquis$274$33,72243 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$46$14,95327 claims
Johnson & JohnsonXarelto$36$9,47120 claims
MerckJanuvia$284$9,08516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →